The focus clearly has shifted to Tx. Almost as if the Dx is

New Post Public Reply Private Reply Replies (0) Message Board
redspeed Trashboy #19494
The focus clearly has shifted to Tx. Almost as if the Dx is a done deal.

Here's the only mention.


Quote:
Amarantus BioScience Holdings (AMBS)

Amarantus is a biotechnology company focused on developing therapeutic and diagnostic products for neurological disorders and orphan indications. The Company has already received Orphan Drug Designation from the FDA for the treatment of Retinitis Pigmentosa.

Amarantus’ lead therapeutic program, eltoprazine is a small molecule indicated for the treatment of Levodopa-induced dyskinesia and is expected to enter a Phase 2b clinical trial in the second quarter of 2015. Eltoprazine is also being evaluated for the treatment of adult attention deficit hyperactivity disorder (ADHD) and Alzheimer’s aggression. Amarantus is developing MANF (mesencephalic-astrocyte-derived neurotrophic factor), for the treatment of brain and ophthalmic disorders.

For further information please visit www.Amarantus.com, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.


http://philasecurities.com/events/ambs/

Amarantus Bioscience Holdings (AMBS) Stock Research Links

AMBS Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

MediaAlpha Set for Q3 2024 Financial Results Presentation

Updated Category News Views 77

MediaAlpha's Upcoming Financial Report Announcement MediaAlpha, Inc. (NYSE: MAX), based in Los Angeles, has exciting news for its investors and stakeholders. The company is gearing up to announce its financial results for the third quarter of 2024 on an upcoming Wednesday. This announcement will take place after the market closes, providing important insights into the...

Continue Reading
BigID Launches Innovative AI Data Access Control Solutions

Updated Category News Views 218

BigID Launches Innovative Solutions for AI Data Access Control Organizations are increasingly leveraging technology in ways that enhance workflows while prioritizing data security. BigID, a leader in the realm of data security and privacy, has introduced a groundbreaking method to prevent unauthorized access to sensitive information in Artificial Intelligence (AI)...

Continue Reading
Latigo Biotherapeutics Secures $150 Million to Innovate Pain Management

Updated Category News Views 442

Latigo Biotherapeutics Secures Major Funding for Pain Relief Advancement Latigo Biotherapeutics, a clinical-stage biotechnology firm dedicated to creating leading non-opioid pain management solutions, has officially closed a substantial $150 million in Series B financing. This funding round aims to push forward the development of their innovative Nav1.8 inhibitor...

Continue Reading
WisdomTree Moves Forward with UK Equity Income Shift

Updated Category News Views 119

WisdomTree's Strategic Shift in UK Equity Income In a significant move, the Directors of WisdomTree Issuer ICAV have officially announced plans to delist the WisdomTree UK Equity Income UCITS ETF. This decision comes as the company aims to merge its focus towards investing in UK Quality Dividend Growth strategies. The shares of this Sub-Fund will no longer be available...

Continue Reading
Avista Foundation's 2024 Grants: Supporting Community Initiatives

Updated Category News Views 384

Avista Foundation's Generous Grants in 2024 In its recent fourth-quarter granting cycle, the Avista Foundation has showcased its unwavering commitment to enhancing community welfare. The foundation distributed a remarkable total of $54,650 to 21 nonprofit organizations across various initiatives aimed at promoting environmental sustainability and enriching arts and...

Continue Reading